Cullinan Therapeutics, Inc.
CGEM- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001789972
In the last 90 days, Cullinan Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 183 institutions reported holding it in 13F filings for Q2 2026, worth $1.31B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Cullinan Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 3 filings
- 1 insider, $922.9K in total
- Insiders trading
- 1
- Net value
- −$922.9K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Cullinan Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Michaelson Jennifer | Chief Scientific Officer | 158,844 | Sep 10, 2026 | 15 |
| Sumer Jacquelyn L | Chief Legal Officer | 130,559 | Jul 2, 2026 | 5 |
| Fenton Mary Kay | Chief Financial Officer | 127,921 | Jul 2, 2026 | 4 |
| Thistle Mary | Director | – | Jun 18, 2026 | 1 |
| Allen Andrew R | Director | – | Jun 18, 2026 | 1 |
| Webster Stephen W | Director | – | Jun 18, 2026 | 1 |
| Rosenberg Anthony | Director | – | Jun 18, 2026 | 1 |
| Meek David D. | Director | – | Jun 18, 2026 | 1 |
| Doyle Mittie | Director | – | Jun 18, 2026 | 1 |
| Ahmed Nadim | President and CEO | 390,803 | Feb 25, 2026 | 4 |
| Jones Jeffrey Alan | Chief Medical Officer | 159,968 | Feb 25, 2026 | 4 |
| Savill Corrine | Chief Business Officer | 240,990 | Feb 19, 2026 | 1 |
| Nichols Weston | 10% Owner | 8,963,500Indirect | Oct 30, 2025 | 3 |
| Lynx1 Capital Management LP | 10% Owner | 8,963,500Indirect | Oct 30, 2025 | 3 |
| Martin Anne-Marie | Director | – | Jun 16, 2025 | 0 |
| Ryan David P. | Director | – | Jun 16, 2025 | 0 |
| Ebeling Thomas | Director | 186,653 | Jun 11, 2024 | 0 |
| Trigilio Jeffrey | Chief Financial Officer | 133,919 | Feb 23, 2024 | 0 |
| Baeuerle Patrick | Chief Scientific Officer | 76,000 | Feb 21, 2023 | 0 |
| Biotechnology Value Fund L P | Other: See Explanation of Responses | 64,161 | Jan 19, 2023 | 0 |
| BVF Partners L P | 10% Owner | 64,161 | Jan 19, 2023 | 0 |
| BVF Inc | 10% Owner | 64,161 | Jan 19, 2023 | 0 |
| Biotechnology Value Fund II LP | Other: See Explanation of Responses | 64,161 | Jan 19, 2023 | 0 |
| Lampert Mark N | 10% Owner | 64,161 | Jan 19, 2023 | 0 |
| Biotechnology Value Trading Fund OS LP | Other: See Explanation of Responses | 64,161 | Jan 19, 2023 | 0 |
| BVF Partners OS Ltd. | Other: See Explanation of Responses | 64,161 | Jan 19, 2023 | 0 |
| BVF I GP LLC | Other: See Explanation of Responses | 64,161 | Jan 19, 2023 | 0 |
| BVF II GP LLC | Other: See Explanation of Responses | 64,161 | Jan 19, 2023 | 0 |
| BVF GP Holdings LLC | 10% Owner | 64,161 | Jan 19, 2023 | 0 |
| Jovan-Embiricos Morana | 10% Owner | 1,255,963 | Aug 4, 2022 | 0 |
| F2 Vision SCS | 10% Owner | 1,255,963 | Aug 4, 2022 | 0 |
| F2 Bioscience I 2017 Ltd | 10% Owner | 537,392 | Jun 23, 2022 | 0 |
| Gadicke Ansbert | Director | 7,648,268Indirect | Jun 23, 2022 | 0 |
| Keane Raymond T | Chief Legal Officer | 24,124 | Feb 15, 2022 | 0 |
| Zawel Leigh | See Remarks | 69,785 | Feb 15, 2022 | 0 |
| MPM BioImpact LLC | 10% Owner | 7,648,268 | Sep 20, 2021 | 0 |
| UBS Oncology Impact Fund L.P. | 10% Owner | 7,648,268 | Sep 20, 2021 | 0 |
| Oncology Impact Fund (Cayman) Management L.P. | 10% Owner | 7,648,268 | Sep 20, 2021 | 0 |
| MPM Oncology Impact Management GP LLC | 10% Owner | 7,805,483 | Aug 25, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 10, 2026 (view filing)9:22 AM ET | Sep 8 | 2 days | Michaelson JenniferChief Scientific Officer | SSale | −8.00K | $21.57 | −$172.6K | −4.8%158.8K after | 10b5-1 |
| Aug 14, 2026 (view filing)5:00 PM ET | Aug 13 | 1 day | Michaelson JenniferChief Scientific Officer | SSale | −30.0K | $20.26 | −$607.8K | −15.6%162.8K after | 10b5-1 |
| Jul 7, 2026 (view filing)5:00 PM ET | Jul 6 | 1 day | Michaelson JenniferChief Scientific Officer | SSale | −8.00K | $17.82 | −$142.6K | −4.7%162.8K after | 10b5-1 |
| May 6, 2026 (view filing) | May 5 | 1 day | Michaelson JenniferChief Scientific Officer | SSale | −8.00K | $14.62 | −$117.0K | −4.6%166.8K after | 2 lots10b5-1 |
| Mar 9, 2026 (view filing) | Mar 5 | 4 days | Michaelson JenniferChief Scientific Officer | SSale | −8.00K | $15.68 | −$125.4K | −4.5%170.8K after | 10b5-1 |
| Feb 26, 2026 (view filing) | Feb 25 | 1 day | Michaelson JenniferChief Scientific Officer | SSale | −1.78K | $14.14 | −$25.2K | −1.0%174.8K after | 10b5-1 |
| Feb 25, 2026 (view filing) | Feb 23-24 | 2 days | Michaelson JenniferChief Scientific Officer | SSale | −5.35K | $14.31 | −$76.6K | −2.9%176.6K after | 2 lots10b5-1 |
| Feb 25, 2026 (view filing) | Feb 24 | 1 day | Ahmed NadimPresident and CEO | SSale | −13.5K | $14.47 | −$195.6K | −3.3%390.8K after | |
| Feb 25, 2026 (view filing) | Feb 24 | 1 day | Jones Jeffrey AlanChief Medical Officer | SSale | −4.58K | $14.47 | −$66.3K | −2.8%160.0K after | |
| Feb 25, 2026 (view filing) | Feb 24 | 1 day | Sumer Jacquelyn LChief Legal Officer | SSale | −3.60K | $14.47 | −$52.1K | −2.7%128.1K after | |
| Feb 23, 2026 (view filing) | Feb 20 | 3 days | Fenton Mary KayChief Financial Officer | SSale | −4.40K | $13.62 | −$59.9K | −3.4%126.4K after | |
| Feb 23, 2026 (view filing) | Feb 20 | 3 days | Jones Jeffrey AlanChief Medical Officer | SSale | −4.98K | $13.62 | −$67.9K | −2.9%164.6K after | |
| Feb 23, 2026 (view filing) | Feb 20 | 3 days | Michaelson JenniferChief Scientific Officer | SSale | −11.7K | $14.08 | −$165.4K | −6.1%182.0K after | 2 lots10b5-1 |
| Feb 23, 2026 (view filing) | Feb 20 | 3 days | Sumer Jacquelyn LChief Legal Officer | SSale | −3.74K | $13.62 | −$51.0K | −2.8%131.7K after | |
| Feb 23, 2026 (view filing) | Feb 20 | 3 days | Ahmed NadimPresident and CEO | SSale | −16.4K | $13.62 | −$223.1K | −3.9%404.3K after | |
| Feb 13, 2026 (view filing) | Feb 12 | 1 day | Michaelson JenniferChief Scientific Officer | SSale | −416 | $12.03 | −$5.00K | −0.3%128.2K after | |
| Jan 23, 2026 (view filing) | Jan 22 | 1 day | Michaelson JenniferChief Scientific Officer | SSale | −4.00K | $12.30 | −$49.2K | −3.0%128.6K after | 10b5-1 |
| Dec 29, 2025 (view filing) | Dec 23 | 6 days | Ahmed NadimPresident and CEO | SSale | −9.92K | $10.01 | −$99.3K | −2.3%420.7K after | |
| Dec 22, 2025 (view filing) | Dec 19 | 3 days | Michaelson JenniferChief Scientific Officer | SSale | −1.34K | $10.01 | −$13.5K | −1.0%132.6K after | 10b5-1 |
| Dec 19, 2025 (view filing) | Dec 18 | 1 day | Sumer Jacquelyn LChief Legal Officer | SSale | −3.48K | $9.67 | −$33.7K | −2.5%135.4K after | |
| Dec 19, 2025 (view filing) | Dec 18 | 1 day | Jones Jeffrey AlanChief Medical Officer | SSale | −4.63K | $9.67 | −$44.8K | −2.7%169.5K after | |
| Dec 19, 2025 (view filing) | Dec 18 | 1 day | Michaelson JenniferChief Scientific Officer | SSale | −2.90K | $9.67 | −$28.0K | −2.1%134.0K after | |
| Dec 16, 2025 (view filing) | Dec 12-15 | 4 days | Michaelson JenniferChief Scientific Officer | SSale | −3.14K | $12.23 | −$38.4K | −2.2%136.9K after | 2 lots10b5-1 |
| Nov 25, 2025 (view filing) | Nov 24 | 1 day | Michaelson JenniferChief Scientific Officer | SSale | −4.00K | $12.30 | −$49.2K | −2.8%138.0K after | 10b5-1 |
| Oct 30, 2025 (view filing)5:13 PM ET | Oct 28 | 2 days | Nichols Weston and 1 other10% Owner | PPurchaseCommon stock, $0.0001 par value per share | +165.7K | $8.40 | +$1.39M | +1.9%8.96M after | |
| Oct 21, 2025 (view filing)7:00 PM ET | Oct 14 | 7 daysLate | Nichols Weston and 1 other10% Owner | PPurchaseCommon stock, $0.0001 par value per share ("Common Stock") | +15.0K | $7.59 | +$114.0K | +0.2%8.56M after | |
| Oct 21, 2025 (view filing)7:00 PM ET | Oct 15-17 | 6 daysLate | Nichols Weston and 1 other10% Owner | PPurchase | +233.7K | $8.51 | +$1.99M | +2.7%8.80M after | 3 lots |
| Oct 10, 2025 (view filing)6:58 PM ET | Oct 8 | 2 days | Nichols Weston and 1 other10% Owner | PPurchaseCommon stock, $0.0001 par value per share ("Common Stock") | +556.3K | $6.46 | +$3.59M | +7.8%7.65M after | |
| Oct 10, 2025 (view filing)6:58 PM ET | Oct 9-10 | 1 day | Nichols Weston and 1 other10% Owner | PPurchase | +903.3K | $6.90 | +$6.23M | +11.8%8.55M after | 2 lots |
| Feb 27, 2025 (view filing) | Feb 25 | 2 days | Jones Jeffrey AlanChief Medical Officer | SSale | −4.89K | $8.53 | −$41.8K | −2.7%174.2K after | |
| Feb 27, 2025 (view filing) | Feb 25 | 2 days | Michaelson JenniferChief Scientific Officer | SSale | −3.76K | $8.53 | −$32.0K | −2.6%142.0K after | |
| Feb 27, 2025 (view filing) | Feb 25 | 2 days | Ahmed NadimPresident and CEO | SSale | −12.5K | $8.53 | −$106.9K | −2.8%430.6K after | |
| Feb 27, 2025 (view filing) | Feb 25 | 2 days | Sumer Jacquelyn LChief Legal Officer | SSale | −3.76K | $8.53 | −$32.0K | −2.7%136.9K after | |
| Jan 7, 2025 (view filing) | Jan 6 | 1 day | Michaelson JenniferChief Scientific Officer | SSale | −4.00K | $12.51 | −$50.0K | −4.0%95.8K after | 10b5-1 |
| Dec 27, 2024 (view filing) | Dec 24 | 3 days | Ahmed NadimPresident and CEO | SSale | −8.40K | $11.87 | −$99.7K | −3.1%263.1K after | |
| Dec 20, 2024 (view filing) | Dec 18 | 2 days | Michaelson JenniferChief Scientific Officer | SSale | −4.69K | $11.41 | −$53.5K | −4.5%99.8K after | |
| Dec 20, 2024 (view filing) | Dec 18 | 2 days | Jones Jeffrey AlanChief Medical Officer | SSale | −4.63K | $11.41 | −$52.9K | −3.9%114.1K after | |
| Dec 20, 2024 (view filing) | Dec 18 | 2 days | Sumer Jacquelyn LChief Legal Officer | SSale | −3.48K | $11.41 | −$39.7K | −3.7%90.7K after | |
| Dec 16, 2024 (view filing) | Dec 12 | 4 days | Michaelson JenniferChief Scientific Officer | SSale | −3.49K | $12.52 | −$43.7K | −3.2%104.5K after | |
| Nov 7, 2024 (view filing) | Nov 5 | 2 days | Michaelson JenniferChief Scientific Officer | SSale | −8.00K | $15.64 | −$125.1K | −6.9%107.9K after | 10b5-1 |
| Sep 9, 2024 (view filing) | Sep 5 | 4 days | Michaelson JenniferChief Scientific Officer | SSale | −8.00K | $18.09 | −$144.7K | −6.5%115.9K after | 10b5-1 |
| Jul 9, 2024 (view filing) | Jul 5 | 4 days | Michaelson JenniferChief Scientific Officer | SSale | −8.00K | $16.33 | −$130.6K | −6.1%123.9K after | 10b5-1 |
| May 8, 2024 (view filing) | May 6-7 | 2 days | Michaelson JenniferChief Scientific Officer | SSale | −63.6K | $28.25 | −$1.80M | −32.9%129.6K after | 3 lots10b5-1 |
| Feb 2, 2024 (view filing) | Feb 1 | 1 day | Savill CorrineChief Business Officer | SSale | −40.0K | $16.18 | −$647.2K | −19.4%166.0K after | 10b5-1 |
| Jan 30, 2024 (view filing) | Jan 29 | 1 day | Savill CorrineChief Business Officer | SSale | −40.0K | $14.09 | −$563.6K | −19.4%166.0K after | 10b5-1 |
| Jan 24, 2024 (view filing) | Jan 22-23 | 2 days | Savill CorrineChief Business Officer | SSale | −40.0K | $12.31 | −$492.5K | −19.4%166.0K after | 3 lots10b5-1 |
| Dec 27, 2023 (view filing) | Dec 26 | 1 day | Ahmed NadimPresident and CEO | SSale | −4.27K | $9.24 | −$39.5K | −3.7%111.5K after | |
| Dec 22, 2023 (view filing) | Dec 21 | 1 day | Jones Jeffrey AlanChief Medical Officer | SSale | −1.86K | $8.50 | −$15.8K | −3.2%56.2K after | |
| Dec 22, 2023 (view filing) | Dec 21 | 1 day | Sumer Jacquelyn LChief Legal Officer | SSale | −1.40K | $8.50 | −$11.9K | −3.1%44.1K after | |
| Dec 22, 2023 (view filing) | Dec 21 | 1 day | Trigilio JeffreyChief Financial Officer | SSale | −1.92K | $8.50 | −$16.3K | −2.2%83.9K after |